UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2022
(Exact name of registrant as specified in its charter)
(state or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (617 ) 314-6297
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 4, 2022, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended June 30, 2022. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | ||||||||
| No. | Description | |||||||
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KEROS THERAPEUTICS, INC. | ||||||||
| By: | /s/ Jasbir Seehra | |||||||
Jasbir Seehra, Ph.D. Chief Executive Officer | ||||||||
Dated: August 4, 2022
Exhibit 99.1
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patients; 44% of high transfusion burden patients achieved transfusion independence
KER-012 preliminary Phase 1 data exhibited encouraging treatment profile in healthy volunteers with improvements in biomarkers of bone formation with no clinically meaningful changes in red blood cell parameters
Strengthened cash position and extended cash runway to fund operations into Q3 2024
LEXINGTON, Mass., August 4, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended June 30, 2022.
“We continued the positive momentum for our pipeline programs into the second quarter of 2022. The clinical data demonstrated the potential of differentiated profiles of KER-050 and KER-012,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “We shared promising clinical data for KER-050 in patients with MDS demonstrating the potential for transfusion independence in RS+ and non-RS patients and in those patients with high transfusion burden. Additionally, we also presented encouraging initial safety and biomarker data for KER-012 from our Phase 1 study in healthy volunteers. We continue making progress and remain on track to report additional data from both studies later this year.”
Recent Program Highlights
•KER-050 for the treatment of ineffective hematopoiesis to address cytopenias associated with myelodysplastic syndromes (MDS) and myelofibrosis (MF)
◦In June 2022, Keros presented data from an ongoing, open-label, two-part Phase 2 clinical trial evaluating KER-050 for the treatment of anemia in patients with very low, low, or intermediate-risk (lower risk) MDS patients at the Annual Congress of the European Hematology Association.
◦As of the data cutoff date (April 3, 2022), 51.9 % of evaluable patients (n=27) achieved overall erythroid response.
◦Importantly, in patients with high transfusion burden (HTB), the overall erythroid response rate (hematologic improvement-erythroid (HI-E) or transfusion independence (TI)) was 68.8 % while 43.8% achieved TI. A 52.9% mean maximum increase in soluble transferrin receptor, a marker of erythropoiesis, was observed with KER-050 treatment. Additionally, a 29.1% mean maximum reduction in serum ferritin, a marker of iron overload was observed with KER-050 treatment.
◦HTB patients achieving HI-E or TI also exhibited a sustained increase in platelets further illustrating the potential that KER-050 has to treat both anemia and thrombocytopenia in MDS patients.
◦KER-050 was generally well-tolerated at all doses evaluated in Part 1, and no drug-related serious adverse events (SAE) or dose-limiting toxicities (DLT) were observed.
◦Following recommendation of the Safety Review Committee, dosing for Part 2 of the KER-050 Phase 2 MDS trial was initiated. The Company expects to report additional data from the trial by end of 2022.
◦KER-050 is also being evaluated in an ongoing Phase 2 trial for treating MF-associated cytopenias and the Company remains on track to report initial data by the end of 2022.
•KER-012 for the treatment of pulmonary arterial hypertension (PAH) and disorders associated with bone loss
◦In May 2022, Keros announced preliminary topline data from the Phase 1 clinical study of KER-012 in healthy postmenopausal women. This is an ongoing randomized, double-blind, placebo controlled, two-part dose-escalation study to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of treatment with KER-012.
◦In the single ascending dose portion of the study, dosing with KER-012 was generally observed to be well tolerated at all doses up to 5 mg/kg with no SAEs noted. Majority of adverse events were mild (Grade 1 category).
◦Maximal target engagement was seen with the 5 mg/kg dose (39.6% mean reduction in follicle-stimulating hormone levels) on day 22 post-treatment.
◦Robust changes in bone formation markers were also observed, with up to 36.4% mean maximal increase in bone specific alkaline phosphatase (BSAP) elicited upon a single treatment of KER-012. These increases are consistent with restoration of bone morphogenic protein (BMP) signaling. Keros believes this supports the development of KER-012 as a potential treatment for patients with PAH, which is associated with reduced BMP signaling.
◦Further, no clinically meaningful changes in hemoglobin, red blood cells or reticulocytes were observed at any dose level.
◦An ongoing multiple ascending dose (MAD) portion of the Phase 1 KER-012 study is expected to report additional data in the second half of 2022. The Company anticipates announcing the design of a Phase 2 trial in PAH in early 2023.
•KER-047 for the treatment of anemias resulting from iron imbalance
◦In June 2022, Keros commenced an open label, two-part, MAD Phase 2 clinical trial to evaluate single (Part 1) and multiple ascending doses (Part 2) of KER-047 in patients with iron-refractory iron deficiency anemia. The Company anticipates reporting initial data from this trial by the end of 2022.
◦The Company expects to initiate a Phase 2 study in iron-deficiency anemia in the second half of 2022 and anticipates reporting initial data in first half of 2023.
•Cash position strengthened
◦The Company has utilized its "at-the-market" shelf registration statement to sell shares of common stock, which strengthened its cash position, and extended its cash runway to fund operations into the third quarter of 2024.
Second Quarter 2022 Financial Results
Keros reported a net loss of $27.3 million in the second quarter of 2022 as compared to a net loss of $15.6 million in the second quarter of 2021. The increase in net loss for the second quarter was largely due to increased research and development efforts as well as additional infrastructure expenses to support the achievement of Keros' corporate goals.
Research and development expenses were $23.3 million for the second quarter of 2022 as compared to $10.0 million for the same period in 2021. The increase of $13.3 million was primarily due to additional research and development efforts, manufacturing activities, and personnel expenses to support the advancement of Keros' pipeline.
General and administrative expenses were $7.4 million for the second quarter of 2022 as compared to $5.7 million for the same period in 2021. The increase of $1.8 million was primarily due to increase in personnel expenses and other external expenses to support Keros' organizational growth.
Keros’ cash and cash equivalents as of June 30, 2022 was $215.6 million compared to $230.0 million as of December 31, 2021. Keros expects that the cash and cash equivalents it had on hand at June 30, 2022 will fund its operating expenses and capital expenditure requirements into the third quarter of 2024.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance. Keros’ third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of disorders associated with bone loss, such as osteoporosis and patients with osteogenesis imperfecta.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potential,” "projects,” “would” and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and timing of its clinical trials for KER-047; the potential impact of COVID-19 on Keros’ ongoing and planned preclinical studies, clinical trials, business and operations; and Keros’ expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its lead product candidates, KER-050 and KER-047; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and risks relating to the impact on Keros' business of the COVID-19 pandemic or similar public health crises.
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 5, 2022, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Deepankar Roy
droy@kerostx.com
213-268-1878
KEROS THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
| THREE MONTHS ENDED JUNE 30, | SIX MONTHS ENDED JUNE 30, | ||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
| REVENUE: | |||||||||||||||||||||||
| License revenue | $ | — | $ | 100 | $ | — | $ | 100 | |||||||||||||||
| Total revenue | — | 100 | — | 100 | |||||||||||||||||||
| OPERATING EXPENSES: | |||||||||||||||||||||||
| Research and development | (23,281) | (9,983) | (41,359) | (21,478) | |||||||||||||||||||
| General and administrative | (7,447) | (5,658) | (13,495) | (9,932) | |||||||||||||||||||
| Total operating expenses | (30,728) | (15,641) | (54,854) | (31,410) | |||||||||||||||||||
| LOSS FROM OPERATIONS | (30,728) | (15,541) | (54,854) | (31,310) | |||||||||||||||||||
| OTHER INCOME (EXPENSE), NET | |||||||||||||||||||||||
| Interest expense, net | — | (1) | (1) | (2) | |||||||||||||||||||
| Research and development incentive income | 3,376 | — | 3,376 | — | |||||||||||||||||||
| Other income (expense), net | 86 | (80) | 27 | (145) | |||||||||||||||||||
| Total other income (expense), net | 3,462 | (81) | 3,402 | (147) | |||||||||||||||||||
| Loss before income taxes | (27,266) | (15,622) | (51,452) | (31,457) | |||||||||||||||||||
| Income tax provision | — | — | — | (50) | |||||||||||||||||||
| Net loss | $ | (27,266) | $ | (15,622) | $ | (51,452) | $ | (31,507) | |||||||||||||||
| Net loss attributable to common stockholders—basic and diluted | $ | (27,266) | $ | (15,622) | $ | (51,452) | $ | (31,507) | |||||||||||||||
| Net loss per share attributable to common stockholders—basic and diluted | $ | (1.13) | $ | (0.67) | $ | (2.14) | $ | (1.35) | |||||||||||||||
| Weighted-average common stock outstanding—basic and diluted | 24,053,977 | 23,305,673 | 24,024,004 | 23,267,943 | |||||||||||||||||||
KEROS THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)
| JUNE 30, 2022 | DECEMBER 31, 2021 | ||||||||||
| ASSETS | |||||||||||
| CURRENT ASSETS: | |||||||||||
| Cash and cash equivalents | 215,621 | 230,042 | |||||||||
| Accounts receivable | — | 18,000 | |||||||||
| Prepaid expenses and other current assets | 6,736 | 3,398 | |||||||||
| Total current assets | 222,357 | 251,440 | |||||||||
| Operating lease right-of-use assets | 658 | 1,067 | |||||||||
| Property and equipment, net | 1,652 | 1,335 | |||||||||
| Restricted cash | 1,327 | 1,327 | |||||||||
| Other long-term asset | 667 | 82 | |||||||||
| TOTAL ASSETS | 226,661 | 255,251 | |||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||
| CURRENT LIABILITIES: | |||||||||||
| Accounts payable | 7,660 | 3,645 | |||||||||
| Current portion of operating lease liabilities | 670 | 862 | |||||||||
| Accrued expenses and other current liabilities | 7,123 | 7,339 | |||||||||
| Total current liabilities | 15,453 | 11,846 | |||||||||
| Operating lease liabilities, net of current portion | — | 231 | |||||||||
| Total liabilities | 15,453 | 12,077 | |||||||||
| STOCKHOLDERS' EQUITY: | |||||||||||
| Common stock, par value of $0.0001 per share; 200,000,000 authorized as of June 30, 2022 and December 31, 2021, respectively; 24,429,382 and 23,974,834 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 2 | 2 | |||||||||
| Additional paid-in capital | 386,413 | 366,927 | |||||||||
| Accumulated deficit | (175,207) | (123,755) | |||||||||
| Total stockholders' equity | 211,208 | 243,174 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 226,661 | 255,251 | |||||||||